



**Food and Drug Administration  
OFFICE OF CRIMINAL INVESTIGATIONS  
REPORT OF INVESTIGATION**

**REPORTING OFFICE:** San Francisco Resident Office

**DOCUMENT NUMBER:** 256977

**CASE NUMBER:** 2010-SFC-735-0280-J

**RELATED CASE NUMBER:** (b) (7)(E)

**TYPE OF CASE:** 735.100, DIETARY SUPPLEMENTS - CDER

**CASE TITLE:** PRIMORDIAL PERFORMANCE

**CASE AGENT:** (b) (7)(F)

**INVESTIGATION MADE AT:** Portland, OR

**INVESTIGATION MADE BY:** SA (b) (7)(F)

**REPORTING PERIOD:** **FROM:** 04/13/2017 **TO:** 07/11/2017

**STATUS OF CASE:** Continued

**SYNOPSIS:** Trial Prep.

\*\*\*\*\*  
**RESTRICTED INFORMATION**  
\*\*\*\*\*

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

**UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION**  
\*\*\*\*\*

**REPORT SUBMITTED BY:** Electronically submitted by (b) (7)(F) \_\_\_\_\_ **DATE:** 07/18/2017  
(b) (7)(F) \_\_\_\_\_, SPECIAL AGENT

**REPORT APPROVED BY:** Electronically approved by LISA MALINOWSKI \_\_\_\_\_ **DATE:** 07/20/2017  
LISA MALINOWSKI, SPECIAL AGENT IN CHARGE

**DISTRIBUTION:** ORIG: SFC

**1. INTRODUCTION:**

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methyldrostanolone. Superdrol (aka methyldrostanolone, aka methasteron) is a designer anabolic steroid <sup>(b) (7)(E)</sup>

<sup>(b) (7)(E)</sup>

Reference is made to the Report of Investigation for the period January 13, 2017 through April 12, 2017.

**2. DETAILS OF INVESTIGATION:**

During this reporting period, Special Agent <sup>(b) (7)(F)</sup> created witness and exhibit lists, collected resumes from potential witnesses, received expert reports from the Center for Food Safety and Applied Nutrition and the Center for Drug Evaluation and Research, responded to defense requests for discovery, and requested discovery.

<sup>(b) (7)(F), (b) (7)(E)</sup>

On June 27, 2017 SA <sup>(b) (7)(F)</sup> received a copy of defense testing of the aliquot inventoried on IE 10-0280-32642 from <sup>(b) (4)</sup>

**3. JUDICIAL ACTION:**

None.

**4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:**

On April 24, 2017 SA <sup>(b) (7)(F)</sup> received a copy of the chain of custody for the aliquot listed on IE 10-0280-32642 from <sup>(b) (4)</sup>

**5. STATUS OF INVESTIGATION:**

Continued.

**6. SUSPECTS/DEFENDANTS/OTHER:**

PRIMORDIAL PERFORMANCE  
ERIC POTRATZ

<sup>(b) (6), (b) (7)(C)</sup>

WWW.PRIMORDIALPERFORMANCE.COM

<sup>(b) (6), (b) (7)(C)</sup>

(b) (6), (b) (7)(C)

[Redacted text block]

**7. ATTACHMENTS:**

None.